A comparison of the effects of adrenaline and noradrenaline in critically ill patients

ISRCTN ISRCTN92846592
DOI https://doi.org/10.1186/ISRCTN92846592
Secondary identifying numbers N/A
Submission date
12/11/2004
Registration date
07/03/2005
Last edited
30/10/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr John Myburgh
Scientific

Intensive Care Unit
The St George Hospital
Gray Street
Kogarah, Sydney
2217
Australia

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific title
Study acronymThe Cat study
Study objectivesThe aim of the Cat study is to compare the clinical effects of adrenaline and noradrenaline in critically ill patients with circulatory dysfunction or failure. It is a prospective, double blind, randomised trial. Patients will be designated a priori into two groups: circulatory failure due to sepsis syndrome/septic shock and circulatory failure due to non-septic causes (cardiogenic shock, normovolaemic hypotension, augmentation of mean arterial pressure). The null hypothesis assumes no difference in resolution of circulatory failure or all-cause mortality in patients with circulatory failure receiving infusions of either adrenaline or noradrenaline.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedCirculatory failure in critically ill patients
InterventionPatients randomised to receive either adrenaline or noradrenaline
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)adrenaline or noradrenaline
Primary outcome measureTime to resolution of circulatory failure to pre-morbid state from commencement of catecholamine.
Secondary outcome measuresICU length of stay and mortality, hospital mortality and 90-day mortality: degree of organ dysfunction during 28-day period (as determined by SOFA scores): cardiovascular, respiratory, renal, neurological, hepatic; and metabolic function.
Overall study start date01/10/2003
Completion date31/10/2005

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants250
Key inclusion criteriaCritically ill patients requiring a catacholamine infusion for cardiovascular support
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/10/2003
Date of final enrolment31/10/2005

Locations

Countries of recruitment

  • Australia

Study participating centre

Intensive Care Unit
Kogarah, Sydney
2217
Australia

Sponsor information

The St George Hospital - Dept of Intensive Care (Australia)
Hospital/treatment centre

Gray Street
Kogarah, Sydney
2217
Australia

ROR logo "ROR" https://ror.org/02pk13h45

Funders

Funder type

Not defined

Not provided at time of registration

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/12/2008 Yes No